Myotrophin recombinant human IGF-1: Ended Phase II/III trial in 266 patients, with results to be presented at a meeting in France June 8-10. An on-going Phase I

Cephalon Inc. (CEPH), West Chester, Penn. Product: Myotrophin recombinant human IGF-1 Indication: Amyotrophic lateral sclerosis Status: Ended Phase II/III trial in 266 patients, with results to be pr...